Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

Takeshi Kitazaki; Mikio Oka; Yoichi Nakamura; Junji Tsurutani; Seiji Doi; Masa Yasunaga; Masaaki Takemura; Hikaru Yabuuchi; Hiroshi Soda; Shigeru Kohno

doi:10.1016/j.lungcan.2005.03.035

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

Identifier:nobleid.org/w1/20260515/6E9ADE48

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6E9ADE48.svg?ark=w1%2F20260515%2F6E9ADE48)](https://nobleid.org/work/w1/20260515/6E9ADE48)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

Identifier:nobleid.org/w1/20260515/6E9ADE48

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6E9ADE48.svg?ark=w1%2F20260515%2F6E9ADE48)](https://nobleid.org/work/w1/20260515/6E9ADE48)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work